Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health is poised for success as its Revita and Rejuva candidates show promise in addressing the root causes of metabolic diseases and its innovative RAPID coverage pathway can speed up the regulatory-reimbursement process. Additionally, the correlation between Revita treatment and weight maintenance and potential for FDA approval and CMS reclassification highlights its potential for growth and success. However, like any clinical stage company, Fractyl Health does face risks in financing, reimbursement, and regulatory challenges that should be carefully monitored.

Bears say

Fractyl Health is facing significant challenges with its Revita and Rejuva candidates as they target root causes of metabolic diseases such as obesity and type 2 diabetes. While positive feedback from the FDA regarding the De Novo filing pathway has been received, uncertainties remain surrounding the safety and efficacy of the candidates, making it difficult to predict their success in the market. Additionally, data from past clinical trials suggest that weight regain is a common issue after discontinuation of similar treatments, raising concerns about the potential durability of Fractyl's products and their long-term impact on patients.

GUTS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 5 analysts, GUTS has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.